Why Fate Therapeutics, Inc.’s (FATE) Stock Is Down 6.68%
As of Friday, October 30, Fate Therapeutics, Inc.’s FATE share price has dipped by 6.68%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Commentary & Analysis
Why Fate Therapeutics, Inc.’s (FATE) Stock Is Up 6.72%
As of Tuesday, October 20, Fate Therapeutics, Inc.’s FATE share price has surged by 6.72%, which has investors questioning if this is right time to sell.Michael Rose
Why Fate Therapeutics, Inc.’s (FATE) Stock Is Up 11.29%
As of Tuesday, October 20, Fate Therapeutics, Inc.’s FATE share price has surged by 11.29%, which has investors questioning if this is right time to sell.Omar Beirat
Why Fate Therapeutics, Inc.’s (FATE) Stock Is Down 5.97%
As of Thursday, September 24, Fate Therapeutics, Inc.’s FATE share price has dipped by 5.97%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Fate Therapeutics, Inc.’s (FATE) Stock Is Down 5.33%
As of Thursday, September 10, Fate Therapeutics, Inc.’s FATE share price has dipped by 5.33%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | FATE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $249.2 | $226.9 | 30% |
|
| Shares Out (Mil) | 120.4 | 53.4 | 66% |
|
| Institutional Ownership | 98.3% | 92.9% | 78% |
|
| Float (Mil) | 105.8 | 40.7 | 61% |
|
| Beta | 2.55 | 0.95 | 96% |
|
| Avg Daily Volume (000s) | 1,201 | 469 | 73% |
|
| Price Change (52-week) |
55.2% | 46.6% | 87% |
|
| Growth | FATE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (26.8%) | 12.8% | 1% |
|
| Net Income (5yr) | 4.7% | (10.1%) | 47% |
|
| EPS (5yr) | 11.4% | 15.8% | 49 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (38.2%) | (15.7%) | 13% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | ($0.255) | ($1.018) | ($0.968) | |
| Month Ago EPS | ($0.255) | ($1.018) | ($0.968) | |
| # Rev Up | 4 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.262) | ($1.039) | ($0.989) | |
| Year/Year Chg | 2.0% | (11.3%) | (5.2%) | |
| Financials | FATE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $7 | $37 | 7% |
|
| Net Income (TTM) (Mil) | ($126) | ($44) | 9% |
|
| EPS (TTM) | ($1.053) | ($1.600) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($102) | ($33) | 6% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $71 | $4 | 42% |
|
| Enterprise Value (Q1) (Mil) | $229 | $174 | 27% |
|
| Valuation | FATE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.59 | 2.17 | 45% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | FATE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.6% | na |
|
| Net Margin | na | (71.5%) | na |
|
| ROA | (39.9%) | (47.1%) | 14% |
|
| ROE | (60.8%) | (53.0%) | 13% |
|
| Liabilities to Assets | 41.0% | 29.6% | 32% |
|
| F-Score | 2 | 2 | 7% |
|
Fate Therapeutics, Inc. did not pass any screens on 10/30/2026.
